Related Experiment Video
Updated: Dec 20, 2025
Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome
Published on: April 2, 2018
Genomic and molecular characterization of pituitary adenoma pathogenesis: review and translational opportunities
Objective:
Innovations in genomics, epigenomics, and transcriptomics now lay the groundwork for therapeutic interventions against neoplastic disease. In the past 30 years, the molecular pathogenesis of pituitary adenomas has been characterized. This enhanced understanding of the biology of pituitary tumors has potential to impact current treatment paradigms, and there exists significant translational potential for these results. In this review the authors summarize the results of genomics and molecular biology investigations into pituitary adenoma pathogenesis and behavior and discuss opportunities to translate basic science findings into clinical benefit.
Methods:
The authors searched the PubMed and MEDLINE databases by using combinations of the keywords "pituitary adenoma," "genomics," "pathogenesis," and "epigenomics." From the initial search, additional articles were individually evaluated and selected.
Results:
Pituitary adenoma growth is primarily driven by unrestrained cell cycle progression, deregulation of growth and proliferation pathways, and abnormal epigenetic regulation of gene expression. These pathways may be amenable to therapeutic intervention. A significant number of studies have attempted to establish links between gene mutations and tumor progression, but a thorough mechanistic understanding remains elusive.
Conclusions:
Although not currently a prominent aspect in the clinical management of pituitary adenomas, genomics and epigenomic studies may become essential in refining patient care and developing novel pharmacological agents. Future basic science investigations should aim at elucidating mechanistic understandings unique to each pituitary adenoma subtype, which will facilitate rational drug design.
Insights
Genomic and epigenomic studies are advancing the understanding of pituitary adenoma development. Future research into these genetic and epigenetic factors could lead to targeted therapies for pituitary tumors.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Recent advancements in genomics, epigenomics, and transcriptomics provide a foundation for novel therapeutic strategies against neoplastic diseases.
- Over the past three decades, significant progress has been made in characterizing the molecular pathogenesis of pituitary adenomas.
- Enhanced understanding of pituitary tumor biology holds potential for transforming current treatment paradigms and offers substantial translational opportunities.
Purpose of the Study:
- To review the findings from genomics and molecular biology investigations into pituitary adenoma pathogenesis and behavior.
- To discuss the potential for translating basic science discoveries into clinical benefits for patients with pituitary adenomas.
Main Methods:
- A comprehensive literature search was conducted using PubMed and MEDLINE.
- Keywords included "pituitary adenoma," "genomics," "pathogenesis," and "epigenomics."
- Relevant articles were individually evaluated and selected for inclusion.
Main Results:
- Pituitary adenoma growth is driven by cell cycle dysregulation, aberrant proliferation pathways, and abnormal epigenetic gene expression.
- While numerous studies have explored gene mutations in tumor progression, a complete mechanistic understanding is still lacking.
- These identified pathways present potential targets for therapeutic intervention.
Conclusions:
- Genomics and epigenomics, though not yet central to clinical pituitary adenoma management, are poised to become crucial for personalized patient care and the development of new drugs.
- Future research should focus on uncovering subtype-specific mechanistic insights into pituitary adenomas.
- Such investigations will be essential for the rational design of targeted pharmacological agents.
